Ra Pharmaceuticals Inc

Ra Pharmaceuticals — Investor Presentation (April 2017)

34 slides from Ra Pharmaceuticals's investor presentation, Apr 4, 2017

  1. Slide 1: Forward Looking Statements

    Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the safety, efficacy and regulatory and clinical progress of our product candidates, incl

  2. Slide 2: Overview

    Overview Focused on complement-mediated diseases Addressing rare hematologic, renal, neurologic indications, as well as ocular and autoimmune Lead clinical program: RA101495 for paroxysmal nocturnal hemoglobinuria (PNH) Potent, synthetic macrocyclic peptide inhibitor of complement C5; Distinct bindi

  3. Slide 3: Leadership Team

    Leadership Team Doug Treco, PhD Co-Founder, President and CEO Ramin Farzaneh-Far, MD Chief Medical Officer David Lubner EVP, Chief Financial Officer Simon Read, PhD Chief Scientific Officer Alonso Ricardo, PhD SVP, Head of Research Jack W. Szostak, PhD Co-Founder 4

  4. Slide 4: Pipeline

    Pipeline (1) Developing an extended release formulation to allow for potential weekly dosing. (2) Leveraging preclinical, CMC and Phase 1 data packages to advance RA101495 in rMG and LN. 5 C5 Inhibition DISCOVERY PRECLINICAL PHASE 1 PHASE 2 RA101495 (PNH; SC) (1) RA101495 (Refractory Myasthenia Grav

  5. Slide 5: The Complement Pathway: A Target-Rich Opportunity

    Q Ra PhaTTna The Complement Pathway A Target-Rich Opportunity for Leveraging our Proprietary Platform Alternative Pathway Classical Pathway Lectin Pathway Activated by non-self cells Activated by antibody-antigen complexes Activated by pathogen surfaces Cciq··c:1··c -1··1 C3 A:f Factor B C2,C3,C4 -C

  6. Slide 6: Our Extreme Diversity Platform

    Our Extreme Diversity™ Platform 7

  7. Slide 7: mRNA Display Platform: A New Approach to Building Drug-like Peptide Libraries

    mRNA Display Platform: A New Approach to Building Drug-like Peptide Libraries and non-natural amino Cyclize to create macrocyclic peptides, convert mRNA to cDNA Large and diverse library of macrocycle peptide-cDNA fusions Large and diverse library of peptide-mRNA fusions P P Affinity selection to im

  8. Slide 8: RA101495 in Paroxysmal Nocturnal Hemoglobinuria (PNH)

    RA101495 in Paroxysmal Nocturnal Hemoglobinuria (PNH) 9

  9. Slide 9: Paroxysmal Nocturnal Hemoglobinuria (PNH)

    RA101495: Paroxysmal Nocturnal Hemoglobinuria (PNH) Rare, chronic, acquired hematologic syndrome where red blood cells (RBCs) are destroyed by the complement system ~16,000 patients worldwide Results in death of 35% of patients within 5 years and 50% within 10 years of diagnosis Most common cause of

  10. Slide 10: Binds a Site on C5 That is Distinct From Eculizumab

    RA101495: Binds a Site on C5 That is Distinct From Eculizumab RA101495 binds in this region 11 Distinct from eculizumab binding site—allows treatment of patients with R885H/C mutations Peptides targeting novel druggable sites provide a toolkit for developing true small molecule inhibitors of C5

  11. Slide 11: Clinical Development Overview

    RA101495: Clinical Development Overview Phase 1, placebo-controlled, single-ascending dose and multiple dose study in healthy volunteers completed 2Q2016 Highly predictable PK after single and multiple SC injections, with dose dependent exposure Suppression of (ex vivo) hemolysis and complement acti

  12. Slide 12: Phase 1 Single-Ascending Dose Cohorts in Healthy Volunteers

    RA101495: Phase 1 Study Single-Ascending Dose Cohorts in Healthy Volunteers Randomized, placebo-controlled, double-blind, safety and dose finding study in healthy volunteers (n=22) 48 hours in-patient monitoring Cohort 1 n=2 RA101495 n=2 Placebo Cohort 2 n=4 RA101495 n=2 Placebo Cohort 3 n=4 RA10149

  13. Slide 13: Pharmacokinetics: Predictable, Dose-Dependent Exposure After Single SC Injections

    RA101495: Pharmacokinetics Predictable, Dose-Dependent Exposure After Single SC Injections Linear relationship observed between Cmax and dose level Approximate terminal half-life across all cohorts is 7 days RA101495 Pharmacokinetics consistent with predicted values from in silico PK model generated

  14. Slide 14: Pharmacodynamics: Strong Suppression of Hemolysis and Complement Activity

    RA101495: Pharmacodynamics Strong Suppression of Hemolysis and Complement Activity After Single SC Injections Direct Hemolysis After a single dose, RA101495 exhibited a rapid dose-dependent inhibition of ex vivo hemolysis and suppression of complement activity in all subjects Maximum PD effect obser

  15. Slide 15: Phase 1 Multiple-Dose Cohort in Healthy Volunteers

    RA101495: Phase 1 Study Multiple-Dose Cohort in Healthy Volunteers Randomized, double-blind, placebo-controlled, multiple-dose study of safety, PK, and PD in healthy volunteers 7 daily doses (8 days in-patient monitoring) n=6 Placebo n=2 0.2 mg/kg n=4 One center: Australia 16 Ciprofloxacin prophylax

  16. Slide 16: PK Model Predicts Plasma Drug Levels in Multiple-Dose Cohort

    RA101495: PK Model Predicts Plasma Drug Levels In Phase 1 Multiple-Dose Cohort Modeling of non-human primates (NHP) and human (healthy volunteer) PK data accurately predicted observed results Consistent pharmacokinetics across all subjects with minimal variability in exposure At a 0.2 mg/kg dose lev

  17. Slide 17: Pharmacodynamics: Robust Suppression of Hemolytic Activity in Multiple-Dose Cohort

    RA101495: Pharmacodynamics Robust Suppression of Hemolytic Activity in Phase 1 Multiple-Dose Cohort Suppression of hemolysis and complement activity was rapid, near-complete and sustained across the dosing period in all subjects Inhibition of hemolysis activity at D8 (24h after receiving the last do

  18. Slide 18: RA101495 Protects Against Complement-Mediated Hemolysis of Type III PNH Erythrocytes

    RA101495 Protects Against Complement-Mediated Hemolysis of Type Dose response III PNH Erythrocytes Drug concentration No drug RA101495 No drug Eculizumab Flow cytometry Serum* Serum + HCl + Eculizumab (1 μM) Serum + HCl + RA101495 (1.2 μM) Serum + HCl Type III Type I+II *18h incubation of PNH RBCs w

  19. Slide 19: Summary

    RA101495: Summary RA101495 is a potent inhibitor of complement C5, designed for convenient daily subcutaneous self-administration Single and repeat SC doses of RA101495 were well tolerated in healthy volunteers RA101495 displayed dose-dependent exposure and consistent and predictable pharmacokinetic

  20. Slide 20: PNH Planned Phase 2 Design

    RA101495: PNH Planned Phase 2 Design Goal: To evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of RA101495 in subjects with PNH Design: Open-label (12 weeks) with long-term extension Global Program addressing 3 PNH populations Eculizumab Naïve Eculizumab Switch Ecu

  21. Slide 21: Planned Phase 2 Design

    RA101495: Planned Phase 2 Design D1 W2 W6 W12 Cohort A (naïve) n=8-12 Review of safety & efficacy 0.3mg/kg Loading Dose Evaluation period for primary efficacy endpoint (change in LDH from baseline to mean of W6-12) W6 Extension Study D1 W2 W12 Cohort B (switch) n=6-8 Review of safety & efficacy 0.3m

  22. Slide 22: Daily Dosing Allows Maintenance of a Stable Drug Level

    Daily Dosing Allows Maintenance of a Stable Drug Level as Compared to Bolus, Biweekly Dosing Daily administration greatly reduces risk of drop in plasma drug levels below minimally efficacious level Daily Dosed Drug weekly Dosed Drug Minimum level needed to prevent hemolysis 0 14 28 Day 23 Plasma Dr

  23. Slide 23: Potential Advantages of a Macrocyclic Peptide Inhibitor of C5

    RA101495: Potential Advantages of a Macrocyclic Peptide Inhibitor of C5 Highly predictable PK, robust PD effects Linear relationship between dose and Cmax Observed from Phase 1 data to maintain >97% hemolysis suppression at 24 hours after last dose Weekly dosing considered feasible Improved control

  24. Slide 24: A Well-Differentiated Profile For Treating PNH

    RA101495: A Well-Differentiated Profile For Treating PNH protein monthly Significant LFT high doses Not adequate for FcRn and C5 for technology Increased risks of infection and Insufficient Increased risk technology Potential to Soliris targeting liver C5 for missed doses saturation of hemolysis dos

  25. Slide 25: Complement Regulation Pipeline

    Complement Regulation Pipeline 26

  26. Slide 26: Building a Complement Inhibitor Franchise

    Building a Complement Inhibitor Franchise Technology enables development of a portfolio of C5 inhibitor candidates suitable for chronic or acute indications Can vary PK properties and route of administration Allows different pricing structures for different indications Life cycle extension plan for

  27. Slide 27: Next Generation of C5 Inhibitors: Orally Bioavailable Small Molecules

    Next Generation of C5 Inhibitors: Orally Bioavailable Small Molecules Series of orally bioavailable (%F=30) small molecules that bind C5, inhibit its cleavage/activation (IC50 14 nM in sheep RBC lysis assay), and prevent hemolysis of PNH erythrocytes in a dose dependent manner Serum + HCl + Eculizum

  28. Slide 28: Therapeutic Use Of Factor D Inhibitors

    Therapeutic Use Of Factor D Inhibitors Factor D (FD) is a critical mediator of alternative pathway activation Cleaves Factor B bound to C3b, generating C3 convertase (C3bBb) FD Potential indications: Dense deposit disease/Membranoproliferative Glomerulonephritis type II/C3 Glomerulopathy (High prior

  29. Slide 29: Factor D: Developing Multiple Molecules for Two Potential Value Streams

    Factor D: Developing Multiple Molecules for Two Potential Value Streams Highly potent inhibitors (low nanomolar) Physical Properties Solubility and Stability (PBS, Plasma, and Log D etc. Vitreous) In vitro DMPK Microsomes, retinal pigmented epithelium stability, CYP profile (including retinal CYPs)

  30. Slide 30: Selective Inhibition of the Classical Pathway: C1 Macrocycle Project

    Selective Inhibition of the Classical Pathway: C1 Macrocycle Project C1 Complex and subunits Multiple approaches to inhibition of C1 complex C1q has an emerging number of non-complement functions Clearance of apoptotic cells and immunogenic debris Tolerance induction in dendritic cells Anti-prolifer

  31. Slide 31: Financial Summary

    Financial Summary $117.8 million in cash and cash equivalents as of December 31, 2016 $105.4 million gross proceeds raised in October, 2016 initial public offering $95.7 million net proceeds Collaboration with Merck represents opportunity for additional milestone and royalty payments Delivered orall

  32. Slide 32: Investment Highlights

    Investment Highlights Focused on complement-mediated diseases Addressing rare hematologic, renal, neurologic indications, as well as ocular and autoimmune Lead clinical program: RA101495 for paroxysmal nocturnal hemoglobinuria (PNH) Potent, synthetic macrocyclic peptide inhibitor of complement C5; D

  33. Slide 33: Contact: Jen Robinson

    Contact: Jen Robinson Senior Director, Investor Relations & Corporate Communications [email protected] 35

  34. Slide 34: Ra Pharma

    Ra/ Pharma Contact: Jen Robinson Senior Director, Investor Relations & Corporate Communications [email protected] 35

Ra Pharmaceuticals — Investor Presentation (April 2017) on 6ix